LDS/Medical Tests/Levetiracetam, Urine

Levetiracetam, Urine

Levetiracetam is classified as an anticonvulsant drug and used to treat epileptic seizures. The class of drugs known as anticonvulsants are designed to help the physician in treating patients with seizures. The most common type of seizure that the physician encounters in clinical medicine are epileptic seizures. Epilepsy is a disease of the brain in which an individual experiences recurrent seizures.  Children may develop seizures as a result of a fever, known as febrile seizures.

The specific type of seizures that levetiracetam is used to treat clinically are partial and secondarily generalized tonic-clonic seizures. Levetiracetam has been developed to aid the physician in treatment of these types of seizures. Levetiracetam is not metabolized to any appreciable extent and excreted into the urine as the glucuronide of the parent drug.

The route of administration of levetiracetam is orally.

Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. Levetiracetam can be analyzed by a variety of analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay, and screening spot testing.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of anticonvulsants and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic level: 12-46 mg/L
Toxic level: >60 mg/L
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.          

Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to not only detect the parent drug, levetiracetam. Levetiracetam can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. Levetiracetam is not extensively bound to protein and usually appears in the urine as the glucuronide conjugate. When analyzing urine specimens a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Urine collected in a sterile urine cup. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Lettleton, MA: PSG Publisging Co.; 1987
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatogr. 1985;340:139-72.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 22, Anticonvulants and Antiarrhythmics, pp. 391-402; 2013.